Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Coegin Pharma has agreed on subscription commitments totalling approx. MSEK 9.8 concerning warrants of series TO3 ("TO3"). The subscription commitments have been made by a group of the company's larger shareholders and correspond to approximately 47 % of the proceeds the company may receive through the exercise of all TO3 warrants.
In connection with the rights issue carried out at the beginning of 2024, a total of 5,279,936 TO3 were issued. Each warrant entitles the holder to subscribe for one new share in Coegin Pharma at a subscription price of SEK 3.90 per share. Subscription with the support of TO3 can take place during the period from 16 September 2024 to 30 September 2024. If all TO3 warrants are exercised for share subscription, the company will receive approximately MSEK 20.6 before issue costs.
Coegin Pharma has received subscription commitments from the following warrant holders:
Subscribers | Commitment (SEK) |
Quarterback Capital AB | 2,000,000 |
Alveco Invest AB | 1,751,381 |
Crystallus AB | 1,083,330 |
Lennart Börjesson | 1,000,000 |
Rune Löderup (privat och genom bolag) | 1,000,000 |
Wilhelm Svenstig AB | 1,000,000 |
Urban Engström | 722,222 |
Bengt Svenstig | 361,109 |
RW-Leasing Aktiebolag | 361,109 |
Br Börjessons Bil AB:s Pensionsstiftelse | 300,000 |
Mathias Rasteby | 200,000 |
Totalt: | 9,779,151 |
The subscription commitments are not secured by a bank guarantee, escrow, pledging, or similar arrangements. No compensation is provided for the subscription commitments.
"We are very pleased with the long-term commitment shown by our major shareholders through these subscription commitments. Their support is a clear testament to their confidence in our future and provides us with the stability we need to continue our launch preparations for our hair growth project FOL005," says Jens Eriksson, CEO of Coegin Pharma.
The full terms of TO3 and the relevant investment memorandum published by Coegin Pharma on 6 February 2024, are available on the company's website, coeginpharma.com.
For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21
This information is information that Coegin Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 08:45 CET on 16 September 2024.
This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.
About Coegin Pharma
Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia. Coegin is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026.
Coegin Pharma's shares are listed on NGM Nordic SME and Börse Stuttgart, and the company has a registered office in Lund, Sweden.
For more information, please visit: coeginpharma.com/en